Global Screening

When Genesis Limited began its multicenter trials, the model was straightforward: engage physician groups in the countries where interested patients were already located. Rather than requiring subjects to travel blind into an unfamiliar program, Genesis ensured that local physicians clinically examined every candidate before they entered the trial. The company hired and appointed medical professionals in each region as clinical investigators, tasking them with inclusion screening — ordering the radiodiagnostics, blood work, and physical examinations needed to determine who was eligible.

It was a logical starting point. Local screening meant patients could be evaluated close to home, by physicians familiar with their medical history, before any experimental intervention began.

Where the Model Reached Its Limits

But as the trials scaled, the cracks in an offsite screening model became clear. Distance introduced friction: communication lapses surfaced between the physicians conducting screening abroad and the surgeons ultimately performing treatment, creating gaps that offsite oversight alone couldn’t close. Inclusion irregularities crept in — inconsistencies that were hard to catch, and harder to correct, across a network of independently operating investigators.

The deeper issue was structural. Screening and inclusion for experimental treatments sit in a regulatory category of their own, and the rules governing them are not uniform across borders. In many of the countries where Genesis had built physician partnerships, licensed medical professionals were regulatorily restricted from carrying out screening or inclusion for experimental protocols at all — a limitation baked into how those jurisdictions treat investigational therapies, regardless of a physician’s willingness or qualifications.

The Turning Point – Consolidation

In 2015, Genesis made the decision to bring screening and inclusion under its own direct oversight, consolidating this critical function in India. The move addressed each limitation of the earlier model at once: it closed the communication gap between screening and treatment by placing both under one coordinated structure, it tightened control over inclusion consistency, and it aligned the company’s practices with the regulatory framework governing foreign clinicians’ involvement in international trials.

This consolidation didn’t just solve an operational problem — it became the structural backbone of what would evolve into the Neural Cell Transplant Protocol. By owning the full chain from screening through treatment, Genesis established the coordination and consistency that selective cerebrovascular administration demands, where the margin for error in patient selection and timing is especially narrow.

A Foundation Still in Use Today

The lesson from this period has stayed with the company as Somata Genesis: precision in cellular therapy isn’t only about the biologic itself, but about the integrity of every step that precedes it. The screening consolidation of 2015 set a standard that continues to shape how Somata Genesis structures its trials — with inclusion, diagnostics, and treatment held under a single, accountable framework, wherever in the world a study runs.